Key Report Takeaways By drug, semaglutide led with 51.35% of the Latin America GLP-1 agonists market share in 2025, while tirzepatide is projected to record the fastest 12.12% CAGR through 2031
What to look for in any compounding pharmacy Regardless of whether you receive tirzepatide from Olympia, Empower, Strive, or another pharmacy, several factors indicate quality and reliability
After the lysis treatment, Hanseniaspora spp
Programs that address only weight will be evaluated against programs that address weight and its downstream burden
CrossRef MASLD as a systemic metabolic disease: expanding the scope of cardiovascular-kidney-metabolic (CKM) syndrome Xiao-Dong Zhou, Qiong-Yue Fan, Giovanni Targher, Christopher D